GO THERAPEUTICS
GO Therapeutics is the only company with the technologies, platforms and know-how to harness the power of the cancer glycoproteome to generate exceptionally tumor-specific antibodies for cancer immunotherapies. By making antibodies to hybrid antigens combining a tumorโs up-regulated protein expression with a proteinโs aberrant glycosylation pattern, we are able to dramatically increase tumor specificity. Our technology clears the hurdles for making drugs that are extremely specific to the cancer cell.
GO THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.gotherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome
Similar Organizations
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Current Advisors List
Current Employees Featured
Founder
Investors List
Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals investment in Funding Round - GO Therapeutics
Official Site Inspections
http://www.gotherapeutics.com
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GO Therapeutics"
GO Therapeutics - Crunchbase Company Profile
Contact Email [email protected] GO Therapeutics is the only company with the technologies, platforms and know-how to harness the power of the โฆSee details»
Go Therapeutics Company Profile 2024: Valuation, Funding
Go Therapeutics General Information Description. Developer of antibodies designed to fight against a novel class of tumor-specific glycoprotein antigens. The company's antibodies target โฆSee details»
GO Therapeutics - LinkedIn
GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors.See details»
Go Therapeutics Inc - Company Profile and News
Company profile page for Go Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
GO Therapeutics - Org Chart, Teams, Culture & Jobs | The Org
View GO Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Go Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials
Explore Go Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 news, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease ...See details»
Go Therapeutics - Company Profile - Tracxn
Aug 17, 2021 Go Therapeutics is focussed on developing tumor-specific antibodies for cancer immunotherapy. It has developed a proprietary platform to identify the sites of O-linked โฆSee details»
GO Therapeutics - Craft
GO Therapeutics has 5 employees across 2 locations and $5 m in total funding,. See insights on GO Therapeutics including office locations, competitors, revenue, financials, executives, โฆSee details»
GO Therapeutics - Work in biotech
GO Therapeutics is developing therapies against cancer by exploiting unique cancer cell targets. An ideal cancer therapeutic would be specific, potent and broad-spectrum, treating a variety of โฆSee details»
GO Therapeutics - VentureRadar
GO Therapeutics identifies sites of O-linked glycosylation on a wide range of proteins targets. The accessibility of these O-glycans at the plasma... ... Find out ...See details»
GO Therapeutics - Overview, News & Similar companies - ZoomInfo
May 31, 2022 Popular Searches Go Therapeutics Inc GO Therapeutics D2MBiotherapeutics D2m Biotherapeutics Inc Gotherapeutics SIC Code 87,873 NAICS Code 54,541 Show more. โฆSee details»
Astellas and GO Therapeutics Enter into Strategic Research and โฆ
Jun 1, 2022 GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics' cancer specific antibodies against โฆSee details»
Astellas and GO Therapeutics Enter into Strategic Research and โฆ
Jun 1, 2022 GO is applying new advances in glycoproteomics to develop antibody-based cancer therapeutics that specifically target cancer cells. Xyphos holds a novel and proprietary ACCEL โฆSee details»
Roche bags anti-cancer bispecific from GO Therapeutics
Oct 2, 2018 Roche is paying $9 million in an upfront fee and near-term milestones for the worldwide rights to GOโs bispecific. As the drug advances, GO is in line to pocket up to $186 โฆSee details»
Go Therapeutics, Inc. (Go Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ โฆ
Collaboration to Accelerate Next-Generation Cancer Treatment TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: โฆSee details»
GO Therapeutics Enters into a License Agreement with Roche
Oct 2, 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- GO Therapeutics, Inc. (GO), a company applying new advances in glycoproteomics to develop antibody-based cancer therapeutics, โฆSee details»
GO Therapeutics Enters into a License Agreement with Roche for โฆ
Oct 2, 2018 For more information please visit www.gotherapeutics.com. Contacts. Emerging Biocommunications, LLC Jeffrey Krasner, 617-840-9806 [email protected]. Release โฆSee details»
Astellas and GO Therapeutics Enter into Strategic Research and โฆ
Jun 1, 2022 Under the terms of the agreement, Xyphos will pay GO Therapeutics US$20.5 million in upfront cash. Milestone and contingency payments could total up to another US$763 โฆSee details»
Kostadin Petrov, Ph.D. - GO Therapeutics
Dr. Petrov is a senior scientist at GO Therapeutics focused on cell biology. An expert on the Hedgehog pathway receptor, Dr. Petrov has served as instructor and lecturer at Simmons โฆSee details»
48x96 PowerPoint Presentation - gotherapeutics.com
Title: 48x96 PowerPoint Presentation Author: PosterPresentations.com Subject: Research poster presentation template Keywords: 48x96 Powerpoint poster template, scientific poster template, โฆSee details»